Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29665304 | 1.00 | LMNA (0.51) | LMNASMN1; SMN2CTSDKCNK3KCNK9 | |
| Hydrochloric Acid SCHEMBL7418150 | 0.98 | LMNA (0.50) | LMNASMN1; SMN2CTSDKCNK3KCNK9 | |
| SCHEMBL148830 | 0.85 | G6PD (0.60) | CTSDCA12CA1CA2CA7 | |
| SCHEMBL30852229 | 0.85 | G6PD (0.60) | CTSDCA12CA1CA2CA7 | |
| SCHEMBL28289248 | 0.85 | KDM4E (0.56) | LMNASMN1; SMN2MAPK1MAPTKDM4E | |
| SCHEMBL165834 | 0.85 | HTT (0.49) | LMNASMN1; SMN2CTSDKCNK3KCNK9 | |
| SCHEMBL7066201 | 0.83 | CTSD (0.51) | SMN1; SMN2CTSDKCNK3KCNK9CA12 | |
| SCHEMBL1004686 | 0.83 | HSD17B10 (0.56) | LMNACTSDKCNK3KCNK9CA12 | |
| SCHEMBL12884732 | 0.83 | KCNK3 (0.51) | SMN1; SMN2CTSDKCNK3KCNK9MAPK1 | |
| SCHEMBL27676520 | 0.82 | ALDH1A1 (0.50) | LMNASMN1; SMN2CA9MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251617-B1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | disclosed |
| US-20230416233-A1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-12-28 | — | — | US | disclosed |
| CN-116583510-A | (aza) quinolin-4-amine derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-111646973-B | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-19 | — | — | CN | disclosed |
| WO-2022112491-A1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| CN-111646973-A | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-09-11 | — | — | CN | disclosed |
| US-20170290838-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9757382-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9499495-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2009-03-05 | — | — | US | disclosed |
| EP-1899307-A1 | 8-ALK0XY-4-METHYL-3, 4-DIHYDR0-QUINAZ0LIN-2-YL AMINES AND THEIR USE AS 5-HT5A RECEPTOR LIGANDS | F. Hoffmann-Roche AG (CH) | 2008-03-19 | — | — | EP | disclosed |
| EP-1868998-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | Insa Rouen (FR) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007000393-A1 | 8-ALK0XY-4-METHYL-3 , 4-DIHYDR0-QUINAZ0LIN-2-YL AMINES AND THEIR USE AS 5-HT5A RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293350-A1 | 8-Alkoxy or cycloalkoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamines | F. HOFFMANN-LA ROCHE AG A SWISS COMPANY (CH) | 2006-12-28 | — | — | US | disclosed |
| EP-1731507-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | Institut National des Sciences Appliquees de Rouen (INSA) (FR) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006103120-A2 | NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | INSA ROUEN (FR) | 2006-10-05 | — | — | WO | disclosed |
| US-4666499-A | Herbicidal 2 methyl-4-phosphinylcinnolinium hydroxide inner salts | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-19 | — | — | US | disclosed |
| US-4620000-A | Method for preparing 4-hydroxycinnolines in a pH controlled system | SHELL OIL COMPANY (US) | 1986-10-28 | — | — | US | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062279-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS | NLN, SNCA, APP | LMNA 1594/4885SMN1; SMN2 403/4885CTSD 402/4885 |
| US-20170290838-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | LMNA 4307/4885SMN1; SMN2 2448/4885CTSD 4093/4885 |
| US-20230416233-A1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | LMNA 3681/4885SMN1; SMN2 4433/4885CTSD 2888/4885 |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | LMNA 4307/4885SMN1; SMN2 2448/4885CTSD 4093/4885 |
| US-20060293350-A1 | 8-Alkoxy or cycloalkoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamines | HTR5A, HTR2C, HTR3A | LMNA 4366/4885SMN1; SMN2 1380/4885CTSD 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.